Rein Therapeutics, Inc. Stock Price, News & Analysis

Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medications for orphan pulmonary and fibrosis conditions, has announced the adjournment of its 2025 Annual Meeting of Stockholders due to lack of quorum. The meeting will reconvene on July 23, 2025, at 9:00 a.m. Eastern Time.

The record date remains May 5, 2025, and stockholders can continue voting until 11:59 p.m. Eastern Time on July 22, 2025. The board strongly recommends voting "FOR" all proposals outlined in the proxy statement filed with the SEC on May 12, 2025. Previously submitted proxies will remain valid unless properly revoked.

Rein Therapeutics (NASDAQ: RNTX) has announced the dosing of its first patient in the RENEW Phase 2 trial of LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The trial will evaluate the safety, tolerability, and efficacy of LTI-03, a novel Caveolin-1-related peptide treatment.

The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial that aims to enroll 120 patients across 50 global sites. Participants must have been diagnosed with IPF within 5 years of screening. The trial's primary endpoint focuses on treatment-emergent adverse events through Week 24, while secondary endpoints measure efficacy through FVC, ppFVC, and HRCT metrics. Rein is collaborating with IQVIA for enrollment, and topline interim data is expected in H1 2026.

Rein Therapeutics (NASDAQ: RNTX) presented two posters at the American Thoracic Society 2025 International Conference supporting their lead asset LTI-03 for treating idiopathic pulmonary fibrosis (IPF). The first poster demonstrated LTI-03's ability to reduce profibrotic proteins and increase solRAGE production without causing cellular necrosis, unlike current treatment nintedanib. The second poster showed LTI-03's potential to sustain type 2 alveolar epithelial cell (AEC2) viability and support AEC2 to AEC1 differentiation. The company's Phase 2 RENEW trial is currently ongoing, with topline interim data expected in the first half of 2026. Additionally, their second-generation peptide LTI-2355 showed promising results in preclinical studies, demonstrating protective effects on normal lung alveolospheres.

Rein Therapeutics (NASDAQ: RNTX) reported Q1 2025 financial results and provided key business updates. The company has initiated the RENEW Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF), with topline interim data expected in H1 2026. The trial will enroll 120 patients to evaluate two dosage levels. Rein secured two patents for LTI-03's formulation and partnered with Qureight for AI-powered image analysis. Financial highlights include: cash position of $7.4M as of March 31, 2025, Q1 net loss of $5.5M ($0.25 per share), and runway extended through September 2025 following $5.28M raised in April transactions. R&D expenses decreased to $3.1M from $3.5M YoY, while G&A expenses reduced to $2.5M from $3.7M.

Rein Therapeutics (NASDAQ: RNTX) has initiated the RENEW Phase 2 trial for its lead drug candidate LTI-03 in idiopathic pulmonary fibrosis (IPF) patients. The trial will enroll approximately 120 patients across 50 global sites, with topline data expected in H1 2026.

The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial testing two dose levels: a low dose cohort (2.5mg BID) and a high dose cohort (5mg BID). The primary endpoint focuses on treatment-emergent adverse events through Week 24, while secondary endpoints include FVC and HRCT measurements.

In the previous Phase 1b trial, LTI-03 demonstrated promising results with positive trends in 7 out of 8 biomarkers in Cohort 2, with 5 showing dose dependence and 4 achieving statistical significance in the combined cohort data.

Rein Therapeutics (NASDAQ: RNTX) has partnered with Qureight Ltd to integrate deep-learning technology into its upcoming Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) treatment. The collaboration follows positive Phase 1b results where LTI-03 showed promising trends in biomarkers, with five showing dose-dependent effects and four achieving statistical significance.

Qureight will provide comprehensive imaging core lab services and AI-powered analysis to evaluate LTI-03's impact on lung structure and function. Their technology will analyze lung imaging data, measure fibrotic, vascular, and airway lung compartments, and identify correlations between volumetric changes and biomarker activity. This integration aims to accelerate the trial process and provide deeper insights into LTI-03's therapeutic potential.

Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.

Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.

Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.

Rein Therapeutics (NASDAQ: RNTX) announced the acceptance of their abstract for presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentation will focus on evaluating alveolar regenerative properties of Caveolin Scaffolding Peptides (CSD) in 3D alveolospheres from IPF and normal donor lung samples.

The poster presentation (P1463) is scheduled for Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET, as part of Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.

Rein Therapeutics (NASDAQ: RNTX) has secured two new U.S. patents (No. 12,280,088 and 12,280,089) for its lead product candidate LTI-03, a synthetic peptide administered through dry powder inhalation. The patents, issued on April 22, 2025, cover both the formulation and therapeutic applications of LTI-03.

The drug features a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. It is being developed to treat various respiratory conditions including:

• Interstitial lung disease (ILD)
• Idiopathic pulmonary fibrosis (IPF)
• Chronic obstructive pulmonary disease (COPD)
• Asthma and other inflammatory or fibrotic lung conditions

The company plans to initiate a Phase 2 clinical trial of LTI-03 in IPF patients during the first half of 2025.